How the ARID1A gene and protein-making process affect bladder cancer
Transcriptional-translational conflict in bladder epithelial homeostasis and cancer
Researchers are looking at how the ARID1A gene and the cell's protein-making machinery change bladder cells and could point to better treatments for people with bladder cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11237131 on NIH RePORTER |
What this research studies
This project studies how loss of the ARID1A gene changes gene activity and the cell's ability to make proteins in bladder cells. Scientists use lab-grown human cells and mouse models that lack ARID1A to see how these changes can either prevent or enable tumor growth. They can turn the protein-making process (translation elongation) up or down to observe effects, and they test drugs that block that process. The goal is to find whether targeting protein synthesis can stop ARID1A-deficient bladder tumors from progressing.
Who could benefit from this research
Good fit: Ideal candidates are people with bladder cancer whose tumors have lost or mutated the ARID1A gene, often identified by tumor genetic testing.
Not a fit: People without bladder cancer or whose tumors do not have ARID1A loss are unlikely to benefit directly from this specific line of research.
Why it matters
Potential benefit: If successful, this work could identify a druggable weakness in some bladder cancers and lead to treatments that block tumor growth in patients whose tumors lack ARID1A.
How similar studies have performed: Preclinical studies, including the investigators' own lab work, suggest blocking translation elongation can harm ARID1A-deficient tumors, but clinical proof in patients is not yet established.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Hsieh, Andrew Caleb — Fred Hutchinson Cancer Center
- Study coordinator: Hsieh, Andrew Caleb
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.